Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
21.69
+1.42 (7.01%)
At close: Dec 5, 2025, 4:00 PM EST
21.90
+0.21 (0.97%)
After-hours: Dec 5, 2025, 7:59 PM EST
Keros Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 246.72 | 3.55 | 0.15 | - | 20.1 | - | |
| Revenue Growth (YoY) | 37798.31% | 2250.99% | - | - | - | - | |
| Cost of Revenue | 154.96 | 173.63 | 135.26 | 87.27 | 55.14 | 33.86 | |
| Gross Profit | 91.76 | -170.08 | -135.11 | -87.27 | -35.04 | -33.86 | |
| Selling, General & Admin | 45.27 | 40.75 | 34.83 | 27.53 | 21.33 | 12.8 | |
| Operating Expenses | 45.27 | 40.75 | 34.83 | 27.53 | 21.33 | 12.8 | |
| Operating Income | 46.49 | -210.83 | -169.94 | -114.79 | -56.37 | -46.66 | |
| Interest Expense | - | - | - | -0 | -0 | -0.01 | |
| Interest & Investment Income | 27.36 | 23.5 | 14.76 | 3.64 | 0.03 | - | |
| Currency Exchange Gain (Loss) | -1.04 | -0.95 | -0.21 | -0.61 | - | - | |
| Other Non Operating Income (Expenses) | 1.24 | 1.24 | 2.4 | 7.08 | -0.38 | 1.13 | |
| Pretax Income | 71.15 | -187.05 | -152.99 | -104.68 | -56.73 | -45.53 | |
| Income Tax Expense | 6.7 | 0.3 | - | - | 2.01 | -0.17 | |
| Net Income | 64.45 | -187.35 | -152.99 | -104.68 | -58.74 | -45.36 | |
| Net Income to Common | 64.45 | -187.35 | -152.99 | -104.68 | -58.74 | -45.36 | |
| Shares Outstanding (Basic) | 41 | 37 | 29 | 25 | 23 | 16 | |
| Shares Outstanding (Diluted) | 41 | 37 | 29 | 25 | 23 | 16 | |
| Shares Change (YoY) | 17.52% | 27.13% | 16.66% | 8.17% | 50.48% | 566.41% | |
| EPS (Basic) | 1.59 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | |
| EPS (Diluted) | 1.57 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | |
| Free Cash Flow | 87.08 | -162.8 | -126.97 | -71.3 | -63.17 | -37.19 | |
| Free Cash Flow Per Share | 2.12 | -4.35 | -4.31 | -2.83 | -2.71 | -2.40 | |
| Gross Margin | 37.19% | - | - | - | -174.34% | - | |
| Operating Margin | 18.84% | -5938.96% | -112543.71% | - | -280.46% | - | |
| Profit Margin | 26.12% | -5277.55% | -101319.21% | - | -292.26% | - | |
| Free Cash Flow Margin | 35.30% | -4585.91% | -84087.42% | - | -314.29% | - | |
| EBITDA | 47.93 | -209.6 | -169.13 | -114.12 | -56 | -46.38 | |
| EBITDA Margin | 19.43% | - | - | - | -278.58% | - | |
| D&A For EBITDA | 1.44 | 1.23 | 0.82 | 0.67 | 0.38 | 0.28 | |
| EBIT | 46.49 | -210.83 | -169.94 | -114.79 | -56.37 | -46.66 | |
| EBIT Margin | 18.84% | - | - | - | -280.46% | - | |
| Revenue as Reported | 246.72 | 3.55 | 0.15 | - | 20.1 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.